Table 1 Patients’ characteristics and... | American Society of Hematology

Table 1

Patients’ characteristics and systemic response to local immunotherapy

Patient	Age	Disease grade	Stage	FLIPI	Previous treatment	Months since diagnosis or treatment	Response IWG 1999²⁴	Response IWG 2007²⁵
1	59	FL 2	IVA	2	None	13	PD	PD
2	66	FL 2	IVA	4	None	5	CR	CR
3	43	FL 1	IVA	2	None	3	SD	SD
4	55	FL 2	IVA	2	None	6	SD	SD
5	72	FL 1	IVA	2	None	6	CR	PR
6	54	FL 2	IIIA	2	None	6	SD	SD
7	62	FL 2	IVA	4	Zevalin	35	SD	SD
8	62	FL 2	IVA	3	Radiotherapy	37	PR	PR
9	40	FL 3A	IVA	1	Rituximab	33	PR*	PR*
10	81	FL 1	IVA	3	None	3	SD	SD
11	53	FL 2	IVA	2	None	9	PD	PD
12	58	FL 2	IVA	2	None	2	SD	SD
13	66	FL 1	IVA	3	None	12	SD	SD
14	33	FL 1	IVA	2	None	13	PR	PR

Patient	Age	Disease grade	Stage	FLIPI	Previous treatment	Months since diagnosis or treatment	Response IWG 1999²⁴	Response IWG 2007²⁵
1	59	FL 2	IVA	2	None	13	PD	PD
2	66	FL 2	IVA	4	None	5	CR	CR
3	43	FL 1	IVA	2	None	3	SD	SD
4	55	FL 2	IVA	2	None	6	SD	SD
5	72	FL 1	IVA	2	None	6	CR	PR
6	54	FL 2	IIIA	2	None	6	SD	SD
7	62	FL 2	IVA	4	Zevalin	35	SD	SD
8	62	FL 2	IVA	3	Radiotherapy	37	PR	PR
9	40	FL 3A	IVA	1	Rituximab	33	PR*	PR*
10	81	FL 1	IVA	3	None	3	SD	SD
11	53	FL 2	IVA	2	None	9	PD	PD
12	58	FL 2	IVA	2	None	2	SD	SD
13	66	FL 1	IVA	3	None	12	SD	SD
14	33	FL 1	IVA	2	None	13	PR	PR

CR, complete response; FLIPI, FL prognostic index; PD, progressed disease; PR, partial response; SD, stable disease.

Cutaneous lymphoma not evaluable by IWG 1999 or 2007.